Video Programs

Long-term zanubrutinib keeps atrial fibrillation risk low while manageable hypertension, neutropenia and infections emerge with continued therapy.

High‑risk del17p CLL patients on single‑agent zanubrutinib show durable progression‑free survival, rivaling outcomes in standard‑risk groups.

High-risk DEL17p CLL patients show durable progression-free survival on single-agent zanubrutinib, matching outcomes seen in standard-risk groups.

Six-year data show continuous zanubrutinib keeps CLL controlled longer than bendamustine-rituximab, including high-risk del17p/TP53 patients.

New FDA-approved zongepanib boosts responses in HER2-mutant lung cancer, delivering durable control with fewer side effects than standard chemo.

Explore why rare HER2-mutant NSCLC is highly aggressive and how broad NGS testing helps identify candidates for new HER2-targeted treatments.

In this segment on advanced renal cell carcinoma, Dr. Wulff explores how the potential incorporation of belzutifan-based regimens into NCCN recommendations could influence future treatment sequencing.

In this segment on advanced renal cell carcinoma, Dr. McGregor introduces emerging data from the LITESPARK-011 study evaluating belzutifan in combination with lenvatinib compared with cabozantinib in previously treated patients.

Learn how myeloma experts sequence CAR T and bispecifics, boost MRD-negative rates, and why academic-community teamwork improves outcomes.

In this segment on advanced renal cell carcinoma, Dr. Wulff transitions the discussion to treatment sequencing after progression on first-line IO-based therapy.

BCMA bispecifics in relapsed myeloma deliver 60–70% responses and year-long PFS, expanding options beyond limited CAR T access.

BCMA bispecifics boost relapsed myeloma responses to 60–70% and extend PFS to 12–18 months, offering durable options beyond CAR-T.

In this segment on advanced renal cell carcinoma, Dr. McGregor focuses on how clinicians move beyond guideline recommendations when multiple appropriate treatment options are available.

In this segment on advanced renal cell carcinoma, Dr. Geynisman raises the increasingly relevant question of how prior adjuvant pembrolizumab or earlier immunotherapy exposure influences treatment selection in the metastatic setting.

In this final segment, the discussion turns to practical challenges patients face during first-line treatment with carboplatin, paclitaxel, and retifanlimab, along with key considerations for optimizing outcomes.

Learn when to treat relapsed myeloma: who can wait, who needs urgent therapy, and why bispecifics plus daratumumab reshape 2026 care.

Learn why MRD negativity drives longer survival in multiple myeloma and when to pair teclistamab with daratumumab after CD38 exposure.

In this segment on advanced renal cell carcinoma, Dr. Wulff focuses on the role of cabozantinib across different treatment settings and how clinicians decide between monotherapy and combination approaches in practice.

In this segment on advanced renal cell carcinoma, Dr. McGregor explores the role of VEGFR TKI monotherapy in patients with favorable risk disease, where NCCN guidelines include both IO-TKI combinations and, in select cases, TKI alone.

Track myeloma treatment shift to quadruplets, MRD-guided goals, and relapse strategies including CAR-T and genomic testing for longer survival.

For early relapsed myeloma, see how patient, disease, and prior therapy guide choices—and why teclistamab plus daratumumab shows standout PFS.

This segment addresses one of the most pressing challenges in advanced SCAC: management after progression on first-line carboplatin, paclitaxel, and retifanlimab.

In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate and poor risk disease based on IMDC criteria and how this influences first-line treatment selection. Dr. McGregor and Dr. Wulff discuss how NCCN recommendations support both IO-IO and IO-TKI combinations in this population, while emphasizing that clinical context often guides the final decision.

In this introductory segment on advanced renal cell carcinoma, Dr. Wulff frames the challenge of selecting among multiple NCCN category 1 first-line regimens, including IO-IO and IO-TKI combinations. Dr. McGregor and Dr. Geynisman discuss how they approach treatment selection in clinical practice when several evidence-based options exist.

This segment addresses 2 key clinical questions following the adoption of chemo-immunotherapy in advanced SCAC: which patients benefit most and how long treatment should be continued.

Multiple myeloma care shifts to four-drug frontline regimens and MRD testing, boosting deep responses and guiding relapse strategies like BCMA CAR-T and genomic profiling.

Learn how to spot myeloma progression, distinguish relapse vs refractory disease, and decide when to treat—especially after lenalidomide maintenance and biochemical relapse.

This segment focuses on the durability of benefit with first-line chemo-immunotherapy in advanced SCAC and how the POD1UM-303 findings are shaping real-world treatment decisions.